Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Most researchers at this dose level transition to 10mg vials for more practical supply management
How can you integrate GLP-1s with pelvic floor physical therapy to build a stronger foundation
for chronic weight management in pediatric patients aged 12 years and older with obesity
FDA-approved semaglutide brands and indications Brand Ozempic (injectable) Approval date December 2017 Indication Type 2 diabetes glycemic control Brand Ozempic (injectable) Approval date January 2020 Indication Cardiovascular risk reduction in T2D Brand Rybelsus (oral tablet) Approval date September 2019 Indication Type 2 diabetes (first oral GLP-1) Brand Wegovy (injectable) Approval date June 2021 Indication Chronic weight management (BMI 30 or 27 with comorbidity) Brand Wegovy (injectable) Approval date March 2024 Indication Cardiovascular risk reduction in adults with obesity and CVD Brand Wegovy (injectable) Approval date August 2025 Indication Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE) Brand Wegovy oral 25 mg pill Approval date December 2025 Indication Chronic weight management (OASIS 4 basis) Brand Ozempic (injectable) Approval date February 2026 Indication CKD progression in T2D (FLOW basis) Research-grade lyophilized semaglutide from supplier sources is not an FDA-approved drug product and is for research use only
Extended Shelf Life: Lyophilized powder remains potent for a longer duration when stored correctly, making it ideal for maintaining a consistent supply
Pre-existing gastrointestinal conditions People with irritable bowel syndrome, gastroparesis, gastroesophageal reflux disease, or chronic constipation are significantly more likely to experience early and intense side effects
